Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors
Pablo Jiménez-Labaig, Oriol Mirallas, Filipa Pereira, Judit Sanz, Enriqueta Felip, Jordi Rodon, Nicoleta Colombo, Matthew D. Galsky, Kevin J. Harrington · 2026
Read Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors by Pablo Jiménez-Labaig, Oriol Mirallas, Filipa Pereira, Judit Sanz, Enriqueta Felip, Jordi Rodon, Nicoleta Colombo, Matthew D. Galsky, Kevin J. Harrington (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13586887.txt.
Description
Pablo Jiménez-Labaig and eight co-authors re-weigh two classic chemotherapy drugs across solid tumors. Their 2026 study is an umbrella review: it pools 11 prior meta-analyses covering 52 studies and 12,683 patients with seven tumor types. Cisplatin and carboplatin both anchor cancer care, yet which one wins on benefit and harm has stayed murky.
The team merged effect sizes into one scale and graded the certainty of each claim. High-certainty proof favored cisplatin for tumor shrinkage in advanced bladder-region cancer, the first result named in the report. Other outcomes, from survival to side effects, varied in strength of proof. The review gives doctors a graded map rather than a single verdict. It also shows where fresh trials are most needed.
Catalog record
| CREATOR | Pablo Jiménez-Labaig, Oriol Mirallas, Filipa Pereira, Judit Sanz, Enriqueta Felip, Jordi Rodon, Nicoleta Colombo, Matthew D. Galsky, Kevin J. Harrington |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |